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Abstract
Background: Gaucher disease (GD) is the most frequent lysosomal storage disorder; type 1 is by far the most
common form. It is characterized by variability in age of onset, clinical signs and progression. It is usually
diagnosed in the first or second decade of life with the appearance of bone pains, splenomegaly and
thrombocytopenia, but the disease may be diagnosed at any age between 1 and 73 years. In the present study,
we report 3 cases with late onset of GD in whom the disease was a surprise finding including one patient with
Parkinson disease. This late onset is described as an adult form of Gaucher disease.
Findings: Molecular investigation showed mutational homogeneity in Tunisian adult patients suffering from GD.
Indeed, all patients carry the p.N370S mutation: two patients at a homozygous state and one patient at compound
heterozygous state.
Conclusion: The p.N370S mutation presents a large variability in the onset of the disease and its clinical
manifestation supporting the view that GD should be considered as a continuum phenotype rather than a
predefined classification.
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Findings
Gaucher disease (GD) is the most frequent lysosomal
storage disorder [1]. It is an autosomal recessive inborn
defect in the glucocerebrosidase gene (GBA)o n 1 q 2 1
leading to enzymatic deficiency of the b-glucocerebrosi-
dase and the accumulation of glycosylceramide substrate
in the macrophage’s lysosomes. GD is characterized by a
considerable phenotypic and genotypic heterogeneity
[2]. There is a wide range of clinical manifestationsfrom
nearly asymptomatic patients who have mild bone pain
up to full spectrum of severe complications with cytope-
nia, hepatosplenomegaly and pathologic fractures [3].
More than 200 mutations were identified along GBA
gene http://www.hgmd.org. In previous studies, investi-
gation of GD showed that p.N370S, p.L444P and
RecNciI mutations were relatively frequent in Tunisian
patients [4,5]. In the present study, we report three
Tunisian adult GD patients including one patient with
Parkinson disease in whom the disease was incidentally
found following bone marrow examination during check
up for thrombocytopenia with splenomegaly. These
cases were investigated for the p.N370S, p.L444P and
RecNciI mutations in GBA gene.
Three patients diagnosed with GD from three unre-
lated families from southern Tunisia were investigated.
The diagnosis was based on the occurrence of hepatos-
plenomegaly associated with hematological abnormal-
ities and/or bone lesions and was confirmed in all
patients by the presence of Gaucher cells.
After the patient’s written informed consent, 5 ml of
blood were collected. DNA was extracted from periph-
eral blood mononuclear cells using the standard salting-
out procedure. DNA samples were then amplified by
polymerase-chain-reaction (PCR) followed by enzymatic
restriction using XhoIa n dNciI to screen for p.N370S
and p.L444P respectively. Sequencing was performed on
an ABI 3130 to detect the three mutations (p.N370S, p.
L444P and RecNciI).
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A 46 years old male was referred to the hematology
departement of Sfax in Southern Tunisia for thrombocy-
topenia (platelet 20 000/mm
3). Clinical examination
showed a voluminous splenomegaly associated with pan-
cytopenia. Neurological symptoms were absent. The
diagnosis of GD was confirmed by bone marrow exami-
nation (Figure 1: A1, A2). The patient underwent partial
splenectomy. Spleen and liver histology showed Gaucher
cells infiltration. The patient did not follow any specific
enzymotherapy. At the age of 51, he started suffering
from pain in his left leg with a complete functional
impairment. Radiological investigations of the leg
showed an Erlenmeyer flask deformity and cortical frac-
ture requiring surgical treatment. A bone biopsy was
performed and revealed the presence of Gaucher cells.
The patient was treated with a cast immobilization and
an antalgic symptomatic treatment. The treatment out-
come showed a limited effectiveness, with no consolida-
tion and persistence of bone pain. An osteosynthesis by
external fixator was then performed. The patient devel-
oped Parkinson disease presented with ataxia, rigidity
and tremor at the age of 52. Family history was negative
for GD although one brother suffered from Schizophre-
n i a .S c r e e n i n go fe x o n s9a n d1 0o fGBA gene revealed
that the patient was compound heterozygous for the p.
N370S and RecNciI mutations.
Case 2
A 35 years old female was referred to the hematology
departement of Sfax with thrombocytopenia (platelet
count 100 000/mm
3). Family history showed no particu-
lar pathologies. The diagnosis of GD was confirmed by
a myelogram and bone marrow biopsy that revealed the
presence of Gaucher cells (Figure 1: B1, B2). Subse-
quently, biochemical analysis of b-glucocerebrosidase
activity in leucocytes confirmed enzyme deficiency. Neu-
rological and osteoarticular examination were normal.
Molecular genetic testing for the three common Gau-
cher mutations revealedhomozygosity for the p.N370S
mutation. The patient being monitored regularly and is
undergoing a therapeutic trial with a substrate reduction
therapy initiated on April 2011.
Case 3
The patient is a 34 year-old female from a consangui-
neous family. Her mother has developed uterine fibroid,
two sisters had cholecystectomy and one brother had a
bone disease. Her husband and her two children are in
a good health. Her initial clinical presentation was an
unexplained bicytopenia (white blood cells of 2905/mm
3
and platelet count 130 000/mm
3) and splenomegaly.
The diagnosis of GD was confirmed by myelogram (Fig-
ure 1: C1, C2). Spleen histology showed Gaucher cells.
Molecular analysis including PCR/RFLP and DNA
sequencing identified the p.N370S mutation at the
homozygous state. The patient underwent a partial sple-
nectomy and the outcome showed improvement of
pancytopenia.
Discussion
To the best of our knowledge this is the second report
describing adult patients with GD in Tunisia and the
first report of an association of GD and Parkinson dis-
e a s ei no u rC o u n t r y .T h ef i r s tr e p o r tb yD a n d a n ae ta l
[6] described a 50 year old patient with GD without any
neurological disorder. Many adult cases with GD have
been reported worldwide. Based on data from the Gau-
cher Registry (ICGG 2008) the p.N370S mutation was
found in 53% of all GD patients and represents the
highest prevalence. About 14% of GD patients were
diagnosed between the age of 31 to 50 year old [7].
Among the patients we report here, two patients were
homozygous for the p.N370S mutation (table 1). Homo-
zygosity for this mutation appears common among GD
type I adult patients [8]. So far, this mutation was found
in 44% of paediatric Tunisian patients with GD [5].
   
  
   
   
A A A1 1 1  A A A2 2 2 
B B B 1 1 1  B B B 2 2 2 
C C C 1 1 1  C C C 2 2 2 
Figure 1 Micorscopic images of Gaucher cells of the three
studied GD patients: A cell with a ‘’sandpaper’’ appearance
was evident. A: Myelogram of Case 1: microscopic image of
Gaucher cells (A1: MGG, X10) and (A2: MGG, X100). B: Myelogram of
case 2: microscopic image of Gaucher cells (B1: MGG, X10) and (B2:
MGG, X100). C: Myelogram of Case 3: microscopic image of Gaucher
cells (C1: MGG, X10) and (C2: MGG, X100). Abbreviation: MGG; May-
Grünwald Giemsa.
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in Tunisia for which the majority of the patients is born
to consanguineous marriages and is homozygous for
deleterious alleles, the p.N370S mutation is encountered
at heterozygous state in combination with other
mutated alleles [5].
One patient (case 1) developed Parkinson disease at
age 52. The co-morbidity of GD and Parkinson disease
has been largely discussed [9-11]. The incidence of Par-
kinson disease seems particularly high among patients
with GD; Bembi and collaborators found four Parkinson
patients (6.9%) among 58 patients with GD [12]. Lach-
mann and Platt found 3 cases of Parkinson disease in
130 patients (2.3%) [13]. The first signs of Parkinson
disease appear at an earlier age in patients with GD
compared to the general population: 48 versus 71 years
average age, respectively [14]. It has been increasingly
recognized that Parkinsonism may be a clinical feature
of GD type I and may even precede its diagnosis [15].
In addition, heterozygosity for certain GBA gene muta-
tions predisposes to a higher risk for Parkinson disease
according to Chérin and collaborators [16]. Whereas, a
recent study presented by Nishioka and collaborators on
395 patients with Parkinson disease and 372 control
subjects did not show a statistically significant associa-
tion with p.K26R, p.K186R and p.N370S in the Tunisian
population (P > 0.05) [11]. The p.N370S mutation was
identified in only one sporadic patient with Parkinson
disease and 3 control subjects indicating that the fre-
quency of this mutation in Tunisian patients is much
l o w e rt h a nt h a to b s e r v e di nA s h k e n a z iJ e w sp a t i e n t s
with Parkinson disease (31%).Furthermore, Spitz and
collaborators reported that most patients with GD never
develop Parkinson disease, suggesting the involvement
of other genetic and/or environmental factors in the GD
process [15].
I th a sb e e ns u g g e s t e dt h a to n l yo n et h i r do ft h e
patients who were homozygote for p.N370S mutation
come to medical attention and that about two thirds
remain asymptomatic throughout life [17]. Carrier
screening programs may lead to the identification of
asymptomatic cases. In the literature, carrier screening
and termination of pregnancy of GD is controversial, in
particular for mild mutations like the p.N370S mutation
[18,19]. In Tunisia, GD like other autosomal recessive
disorders [20,21], is rare and does not represent a major
public health concern. We suggest that prenatal diagno-
sis for couples at risk carrying a severe mutation
(L444P, RecNciI) is the best alternative to reduce the
incidence of the severe form of the disease.
There is a great variability in the clinical manifestation
as well as in the onset and course of GD. This supports
the need for a new classification and reinforces the
hypothesis of the concept of a phenotypic continuum.
Clinicians, especially in hematology and internal medi-
cine, should suspect the diagnosis of GD in any adult
patient suffering from abdominal and/or bone pain with
unexplained hematological disorder especially in combi-
nation with organomegaly.
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